Selective inhibition of SIN3 corepressor with avermectins as a novel therapeutic strategy in triple negative breast cancer

Triple negative breast cancers (TNBC) lacking estrogen, progesterone and HER2 receptors account for 10–20% of breast cancer and are indicative of poor prognosis. The development of effective treatment strategies therefore represents a pressing unmet clinical need. We previously identified a molecula...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Mol Cancer Ther
Main Authors: Kwon, Yeon-Jin, Petrie, Kevin, Leibovitch, Boris A., Zeng, Lei, Mezei, Mihaly, Howell, Louise, Gil, Veronica, Christova, Rossitza, Bansal, Nidhi, Yang, Shuai, Sharma, Rajal, Ariztia, Edgardo V., Frankum, Jessica, Brough, Rachel, Sbirkov, Yordan, Ashworth, Alan, Lord, Christopher J., Zelent, Arthur, Farias, Eduardo, Zhou, Ming-Ming, Waxman, Samuel
פורמט: Artigo
שפה:Inglês
יצא לאור: 2015
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4529816/
https://ncbi.nlm.nih.gov/pubmed/26078298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0980-T
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים